Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven®) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery
暂无分享,去创建一个
M. Al Douri | T. Shafi | Osman Musa | D. A. al Khudairi | E. Al Bokhari | L. Black | N. Akinwale | A. A. Homaidhi | Al M. Fagih | Borum R. Andreasen
[1] J. Oliver,et al. A possible mechanism of action of activated factor VII independent of tissue factor. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[2] U. Hedner. Recombinant activated factor VII as a universal haemostatic agent. , 1998, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.
[3] K. Reddy,et al. Recombinant factor VIIa corrects prothrombin time in cirrhotic patients: a preliminary study. , 1997, Gastroenterology.
[4] C. Négrier,et al. The Treatment of Bleeding in Acquired Haemophilia with Recombinant Factor VIIa: A Multicentre Study , 1997, Thrombosis and Haemostasis.
[5] E. Cameron,et al. Reoperative mitral valve surgery via right thoracotomy: decreased blood loss and improved hemodynamics. , 1996, The Journal of heart valve disease.
[6] P. Steg,et al. A Patient with Glanzmann Thrombasthenia and Epistaxis Successfully Treated with Recombinant Factor Vila , 1996, Thrombosis and Haemostasis.
[7] U. Mellqvist,et al. Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. , 1996, Haemostasis.
[8] M. Pfisterer,et al. Aprotinin in Aortocoronary Bypass Surgery: Increased Risk of Vein-Graft Occlusion and Myocardial Infarction? Supportive Evidence from a Retrospective Study , 1996, Thrombosis and Haemostasis.